Live vaccines pose risks when using Cosentyx due to the immunosuppressive effect of the drug. Cosentyx, also known as secukinumab, is a biologic medication used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. By inhibiting the protein interleukin-17A, Cosentyx alters the immune response, which can make vaccines less effective and increase the risk of adverse reactions to live vaccines [1][2].

Live vaccines contain weakened but still live viruses or bacteria, which can multiply in the body and trigger an immune response [3]. When a person takes Cosentyx, their immune system's ability to fight off these weakened organisms is reduced, increasing the risk of infection and potential complications [2].

Healthcare providers should assess the necessity of live vaccines for individuals taking Cosentyx and consider alternative vaccine options or delaying immunization until after discontinuing the medication [2]. Patients should consult their healthcare providers before receiving any vaccinations while on Cosentyx [1].

In summary, live vaccines pose risks when using Cosentyx because the drug's immunosuppressive effect can increase the risk of infection and complications from live vaccines. Healthcare providers should carefully consider vaccination options for patients taking Cosentyx [1][2][3].

Sources:
[1] <https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX>
[2] <https://wwwnc.cdc.gov/travel/yellowbook/2024/additional-considerations/immunocompromised-travelers>
[3] <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125504s013lbl.pdf>